📝 Chai Discovery raises $130M

In partnership with

News of the Day

Chai Discovery has secured a massive $130 million Series B funding round. The company has emerged as a vanguard in the high-stakes effort to transform biological research into a programmable engineering discipline, leveraging its “Chai-2” architecture to collapse decades of traditional molecular trial-and-error into mere weeks. By securing a strategic partnership with Eli Lilly, they are challenging the "artisanal" legacy of drug discovery with a generative model that boasts a 16% experimental hit rate for de novo antibodies, a staggering 100-fold improvement over traditional high-throughput screening. This technological leap coincides with Eli Lilly’s separate billion-dollar "co-innovation lab" alliance with Nvidia, signaling a broader industry pivot where the "art" of medicine is being aggressively redefined by specialized, homegrown AI capable of designing first-in-class molecules with atomic precision. While skeptics remain wary of the transition from in silico prediction to clinical success, Chai’s ability to move from computer design to lab-validated results in under 14 days suggests a future where the next generation of life-saving therapeutics may be engineered at the same speed as software, potentially placing novel treatments into clinical trials as early as 2027.

If you have tweets you want to submit to be featured here (from you or someone you like), reply to this email with a link!

Chart of the Day